share_log

BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

BioNTech | 6-K:外国发行人报告
美股SEC公告 ·  04/08 07:17
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息